Muscle pain in models of chemotherapy-induced and alcohol-induced peripheral neuropathy

Authors

  • Pedro Alvarez DVM, PhD,

    1. Oral and Maxillofacial Surgery, University of California, San Francisco, San Francisco, CA
    2. Division of Neuroscience, University of California, San Francisco, San Francisco, CA
    Search for more papers by this author
  • Luiz F. Ferrari DDS, PhD,

    1. Oral and Maxillofacial Surgery, University of California, San Francisco, San Francisco, CA
    2. Division of Neuroscience, University of California, San Francisco, San Francisco, CA
    Search for more papers by this author
  • Jon D. Levine MD, PhD

    Corresponding author
    1. Oral and Maxillofacial Surgery, University of California, San Francisco, San Francisco, CA
    2. Medicine, University of California, San Francisco, San Francisco, CA
    3. Division of Neuroscience, University of California, San Francisco, San Francisco, CA
    • University of California San Francisco, C-555, Box 0440, 521 Parnassus Avenue, San Francisco, CA 94143-0440
    Search for more papers by this author

Abstract

Objective:

While inflammatory pain is well described in skeletal muscle, neuropathic muscle pain remains to be clarified. We used 3 well-established rodent models of peripheral neuropathy to evaluate for muscle pain.

Methods:

In rats exposed to either of 2 neurotoxic cancer chemotherapies, paclitaxel or oxaliplatin, or to alcohol consumption, we assessed the evolution of mechanical hyperalgesia in skeletal muscle and skin, in the same animal. To explore the involvement of protein kinase C epsilon (PKCε), a second messenger implicated in some forms of neuropathic pain, antisense oligodeoxynucleotides (AS-ODNs) or mismatch ODNs (MM-ODNs) for PKCε were administered intrathecally.

Results:

Rats submitted to models of chemotherapy-induced and alcohol-induced neuropathy developed persistent muscle hyperalgesia, which evolved in parallel in muscle and skin. The administration of PKCε AS, which has been shown to mediate cutaneous hyperalgesia in paclitaxel and ethanol models of neuropathic pain, also inhibited muscle hyperalgesia induced by these agents. Stopping AS-ODN was associated with the reappearance of hyperalgesia at both sites. The AS-ODN to PKCε treatment was devoid of effect in both muscle and skin in the oxaliplatin neuropathy model.

Interpretation:

Our results support the suggestion that neuropathic muscle pain may be a greater clinical problem than generally appreciated. ANN NEUROL 2011;

Ancillary